Cogent Biosciences reported two pivotal clinical wins for bezuclastinib, including a Phase 3 trial that halved the risk of progression or death in imatinib‑resistant GIST and supportive data in systemic mastocytosis. The results pushed the company toward two planned NDA filings—one in gastrointestinal stromal tumors in H1 2026 and another for systemic mastocytosis later in 2025. Investors reacted positively, sending shares sharply higher as the company advanced regulatory timelines. Cogent’s dual successes highlight targeted KIT inhibition as a viable route for difficult‑to‑treat kinase‑driven tumors and create a near‑term commercial inflection point for the company.